Menter Dermatology Research Institute
M enter Dermatology Research Institute was established to address the ongoing need for new, clinically safe and effective treatments for physically and psychologically debilitating skin diseases. Although we have a significant and long standing interest in psoriasis research and treatment, we are pleased to be offering clinical studies for a wide range of cutaneous manifestations such as atopic dermatitis, hidradenitis suppurativa, skin cancers, and pyoderma gangrenosum inter alia.
After years of dedication to psoriasis research, including involvement in over 150 clinical research trials in past 35 years, in 2011 Dr. Alan Menter opened a specialty Research Center in Dallas, Texas. Menter Dermatology Research Institute (MDRI) was established to combine Dr. Menter’s interest in both clinical Dermatology and Research locally, nationally, and internationally. For years, Dr. Menter has been involved in clinical research trials for psoriasis and considered a leader and innovator in psoriasis treatment. His dedication has put him at the frontier of investigational therapies in psoriasis and he has now expanded his research interest through clinical trials in a host of other dermatologic disease processes.
For further information regarding any available research studies, please review our “Current Clinical Trials” or contact us toll free at (855) 554-6374.
Menter Dermatology Research Institute is Committed to a Cure
A special tribune honoring Dr. Alan Menter for his commitment to a cure for psoriasis raised $1.175 million. Read more…
MDRI is Enrolling for Clinical Trials
Current Clinical Trials:
We are always adding new clinical studies to Menter Dermatology Research Institute. If we currently don’t have a clinical trial for you, sign up to receive “Future Study Alert” to be informed of future studies.
Dr. Alan Menter
Dr. Menter has a long-held interest in psoriasis and psoriatic disease research that has spanned everything from ultraviolet phototherapy and new biologic therapy to the mapping of genetic patterns to predict whether a person is at risk of developing psoriasis pharmacogenomics.